Biosimilar Policies To Watch As We Approach 2019
Biosimilar Policies To Watch As We Approach 2019

I reached out to Biosimilar Development editorial board member Molly Burich of Boehringer Ingelheim for her input on the policies she expects could have the largest positive or negative impact on biosimilars, as well as what progress has been made on the policy front.

  • Biosimilar Regulatory Inefficiencies: Would Data Sharing Violate The U.S. Constitution?
    Biosimilar Regulatory Inefficiencies: Would Data Sharing Violate The U.S. Constitution?

    In the global biosimilars industry, regulations are administered locally, on a country-by-country basis, inevitably leading to inefficiencies and contradictions in regulatory requirements for biosimilar approval from one country to the next. If those inefficiencies are too great, some companies may delay or forego entirely seeking approval in a jurisdiction where the costs or uncertainties of the regulatory path are too high. 

  • Biosimilars, Biobetters, Or Both?: Report Highlights Manufacturing Considerations
    Biosimilars, Biobetters, Or Both?: Report Highlights Manufacturing Considerations

    I sat down with Kate Hammeke, VP of Industry Standard Research to discuss the biggest surprises or takeaways from this year’s report about the industry’s biologics and biosimilars manufacturing goals. But the conversation also evolved to some of the larger trends Hammeke expects to see impacting the biosimilar players in the future.

  • The Humira Biosimilar Tsunami Cometh: What Can We Expect?
    The Humira Biosimilar Tsunami Cometh: What Can We Expect?

    In the first segment of this two-part Q&A article, da Silva and Heller share their perspectives on the EU market potential for Humira biosimilars, which markets they expect will be most dynamic from a competition standpoint, and what Humira biosimilar players can learn from previous tumor necrosis factor (TNF) biosimilar launches.

  • What To Watch For In The Implementation Of FDA’s Biosimilar Action Plan
    What To Watch For In The Implementation Of FDA’s Biosimilar Action Plan

    In July 2018, the FDA unveiled a Biosimilar Action Plan (BAP) intended to “facilitate the efficient development and approval” of biosimilar products. When FDA Commissioner Scott Gottlieb introduced the BAP, he emphasized the importance of building a market for biosimilar products and expressed concern that the market is not yet established.

  • Biosimilar Education: The Elements Of An Effective Strategy
    Biosimilar Education: The Elements Of An Effective Strategy

    In this first of what I expect will be several articles, I will lay out one of the current educational gaps I’ve noticed, as well as introduce real educational examples or efforts I’ve encountered (or would like to see more of) that show promising and widely adaptable pathways forward.

  • Off The Beaten Path: 3 Strategies For Improving World-Wide Biosimilar Access
    Off The Beaten Path: 3 Strategies For Improving World-Wide Biosimilar Access

    Low- and middle-income nations naturally demand different approaches, and, there is, of course, still much work to be done to bolster biologics use in these countries. This article continues that discussion, illuminating several specific strategies companies can explore to better reach a wide variety of countries and patients.

  • Charting A Biosimilar Course In Low- And Middle-Income Nations
    Charting A Biosimilar Course In Low- And Middle-Income Nations

    Though entering some of these nations will not be for the faint of heart, Iyer believes the solution to these access issues is closer than we realize.

  • Could Naive Patients Be The Key To U.S. Biosimilar Success?
    Could Naive Patients Be The Key To U.S. Biosimilar Success?

    A decade after the primary negotiations that resulted in the BPCIA, it is safe to say the promise of biosimilars is yet to be realized. As it turns out, perhaps naivety, in a clinical sense, is the solution.

  • How Can We Make FDA’s Biosimilar Action Plan A Game-Changer?
    How Can We Make FDA’s Biosimilar Action Plan A Game-Changer?

    Despite all the FDA’s efforts to increase review time and get products to market more quickly, I remain unconvinced that the BAP will turn around the U.S. market — at least not our current market. So what can we do in the meantime?

More Biosimilar editorial...

BIOSIMILAR INSIGHTS

More From Biosimilar...

TRAINING COURSES

24th Annual Validation Week October 22 - 24, 2018
San Diego, CA)
IRT 2018 October 22 - 23, 2018
Philadelphia, PA)
eCOA/ePRO 2018 October 23, 2018
Philadelphia, PA)
MedTech Reimbursement Summit October 24 - 25, 2018
Dallas, TX)
CRO Oversight Post ICH GCP E6 (R2) Addendum October 24 - 24, 2018
1pm-2:30pm EDT, Online Training)
Duration:  90 Minutes
Price:  $299 - Includes Bonus Handouts!
Stability Programs - Key Factors in Meeting FDA/ICH Expectations October 25 - 25, 2018
1pm-2:30pm EST, Online Training)
Price:  $299 - Includes Bonus Handouts!
The Investigational New Drug (IND) Submission – Tips to Win the First Time November 2 - 2, 2018
1pm-2:30pm EDT, Online Training)
Price:  $299 - Includes Bonus Handouts!
Medical Devices - Effective Complaint Handling and Management November 2 - 2, 2018
1pm-2:30pm EST, Online Training)
Price:  $299 - Includes Bonus Handouts!
Independent Expert Committees November 6 - 7, 2018
Amsterdam)
Independent Expert Committees November 6 - 7, 2018
Amsterdam)
More Upcoming Courses
Anna Rose Welch article header

 EVENTS

24th Annual Validation Week October 22 - 24, 2018
San Diego, CA)
IRT 2018 October 22 - 23, 2018
Philadelphia, PA)
eCOA/ePRO 2018 October 23, 2018
Philadelphia, PA)
MedTech Reimbursement Summit October 24 - 25, 2018
Dallas, TX)
CRO Oversight Post ICH GCP E6 (R2) Addendum October 24 - 24, 2018
1pm-2:30pm EDT, Online Training)
Duration:  90 Minutes
Price:  $299 - Includes Bonus Handouts!

LIFE SCIENCE EVENTS

24th Annual Validation Week October 22 - 24, 2018
San Diego, CA
IRT 2018 October 22 - 23, 2018
Philadelphia, PA
eCOA/ePRO 2018 October 23, 2018
Philadelphia, PA
MedTech Reimbursement Summit October 24 - 25, 2018
Dallas, TX
CRO Oversight Post ICH GCP E6 (R2) Addendum October 24 - 24, 2018
1pm-2:30pm EDT, Online Training
More Events...

LIFE SCIENCE INDUSTRY EVENTS

24th Annual Validation Week October 22 - 24, 2018
San Diego, CA
IRT 2018 October 22 - 23, 2018
Philadelphia, PA
eCOA/ePRO 2018 October 23, 2018
Philadelphia, PA
MedTech Reimbursement Summit October 24 - 25, 2018
Dallas, TX
CRO Oversight Post ICH GCP E6 (R2) Addendum October 24 - 24, 2018
1pm-2:30pm EDT, Online Training
More Industry Events

ABOUT BIOSIMILAR DEVELOPMENT

Biosimilar Development is dedicated to presenting technical information, thought leadership, and commentary for the biosimilar development and manufacturing community. On this site, users will find exclusive and actionable content on the industry trends and challenges affecting the emerging biosimilars market. Browse our articles, case studies, and white papers on topics related to biosimilar development, manufacturing, quality, distribution, FDA guidance, BPCIA, global markets, government regulations, and intellectual property.

Biosimilar Development is part of the Life Science Connect media group, which strives to facilitate connections and foster collaborations in pharmaceutical development to find ways to get more life-saving and life-improving therapies to market. Connect, Collaborate, Contribute.